Moderna to present late-breaking Phase 3 melanoma data for intismeran autogene at ESMO 2026

MRNA•2026-09-21

ESMO 2026 presentations planned for intismeran autogene

Moderna flagged three ESMO Congress 2026 presentations on intismeran autogene, an individualized mRNA neoantigen therapy developed with Merck.

Late-breaking Phase 3 melanoma data are scheduled for Oct. 24, 2026, signaling an upcoming readout for a pivotal adjuvant program.

Earlier-stage updates in pancreatic cancer and early-stage NSCLC are also slated for poster sessions, extending the product’s potential across multiple tumors.

Results have not yet been presented; disclosures are planned for Oct. 23-27, 2026, in Madrid.

Moderna to present late-breaking Phase 3 melanoma data for intismeran autogene at ESMO 2026

ESMO 2026 presentations planned for intismeran autogene

Related News

ADM plans voluntary carbon removal credits from 800,000-ton-a-year Nebraska CCS facility

L3Harris Technologies Signs Multi-Year Agreement With Naval Air Warfare Center

Siemens Healthineers teams with Novo to expand non-invasive testing access for MASLD and MASH patients

Rogers Bank, Mastercard, Flybits pilot AI-driven agentic commerce payments in Canada

Colgate-Palmolive announces R$ 0.26 per unit dividend for Q4 2026